Jiangsu hengrui Pharmaceutical Co., Ltd. was established in 1970, formerly known as Lianyungang Pharmaceutical Factory. Is a large-scale pharmaceutical listed enterprise integrating scientific research, production and sales, headquartered in Lianyungang City, Jiangsu Province.
According to the statistics of Rong Yun, 33 new drugs 1 have been approved for clinical use (including supplementary applications) in Hengrui Pharma. By August 2022, Hengrui has 1 1 innovative drugs, covering VEGF, PD- 1, PARP and other targets, involving tumor, blood, analgesia, anesthesia and hypoglycemic treatment. On July 2, 2023, Hengrui Pharma announced that its subsidiary had obtained the notice of approval for clinical trial of HRS-4357 injection drug.
main products
Hengrui has obtained more than 20 registration documents in Europe, America and Japan, including injections, oral preparations and inhaled anesthetics, which has improved the drug accessibility of patients in different regions of the world. By the end of 2022, Hengrui Pharma products have entered more than 40 countries. In the past year, Hengrui actively expanded into emerging markets such as Southeast Asia, Latin America and Russia, and continued to penetrate into developed markets in Europe and America, hoping to help patients around the world obtain and safely use the company's quality products at reasonable prices.
On the evening of May 18, 2022, Hengrui Pharma announced that Guangdong Hengrui Pharma Co., Ltd. and Suzhou Shengdiya Biomedical Co., Ltd., subsidiaries of the company, received the approval notice of clinical trial of SHR-20 10 injection approved by the State Pharmaceutical Products Supervision and Administration, and will conduct clinical trials in the near future. On May 26th, 2022, Hengrui Pharma announced that HR 19042 Capsule had obtained the approval notice of drug clinical trial.
The above contents refer to Baidu Encyclopedia-jiangsu hengrui Pharmaceutical Co., Ltd.